Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 870 results for score

  1. Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

    Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.

  2. Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease (HTG318)

    Evidence-based recommendations on endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. This involves using heat from electrodes to change the tissues in the oesophagus, with the aim of reducing symptoms.

  3. Prosthetic intervertebral disc replacement in the cervical spine (HTG217)

    Evidence-based recommendations on prosthetic intervertebral disc replacement in the cervical spine. This involves removing the damaged disc and inserting an artificial disc in its place.

  4. Upadacitinib for treating severe rheumatoid arthritis (TA665)

    Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults.

  5. Cardiovascular disease prevention: risk assessment (general population) (IND269)

    This indicator covers the percentage of people aged 45 to 84 years who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  6. Siponimod for treating secondary progressive multiple sclerosis (TA656)

    Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.

  7. TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .

  8. Avelumab for untreated metastatic Merkel cell carcinoma (TA691)

    Evidence-based recommendations on avelumab (Bavencio) for untreated metastatic Merkel cell carcinoma in adults.

  9. Lower urinary tract symptoms in men (QS45)

    This quality standard covers diagnosing and managing lower urinary tract symptoms in men (aged 18 and over). It describes high-quality care in priority areas for improvement.

  10. Tofacitinib for moderate to severe rheumatoid arthritis (TA480)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis in adults.

  11. Erectile dysfunction: Alprostadil cream (ESNM50)

    Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making

  12. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (CG115)

    This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.

  13. Osteoarthritis in over 16s (QS87)

    This quality standard covers diagnosing, assessing and managing osteoarthritis in adults aged over 16. It includes treatment and support, and referral for joint surgery. It describes high-quality care in priority areas for improvement.

  14. Autologous blood injection for tendinopathy (HTG299)

    Evidence-based recommendations on autologous blood injection for tendinopathy. This involves supplying the tendon with growth factors that start the healing process.